Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination

Hypertriglyceridemia has emerged as an independent risk factor for cardiovascular events, despite low-density lipoprotein-cholesterol (LDL-C) well-controlled with statins. We pooled data from the first 12 weeks of six randomized double-blind placebo-controlled studies of pemafibrate in Japan and inv...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Int J Mol Sci
Main Authors: Yamashita, Shizuya, Arai, Hidenori, Yokote, Koutaro, Araki, Eiichi, Matsushita, Mitsunori, Nojima, Toshiaki, Suganami, Hideki, Ishibashi, Shun
Formato: Artigo
Idioma:Inglês
Publicado: MDPI 2019
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6888510/
https://ncbi.nlm.nih.gov/pubmed/31698825
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms20225537
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares